What is the share price of Remedium Lifecare Ltd (REMLIFE) today?
The share price of REMLIFE as on 7th March 2025 is ₹2.52. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Remedium Lifecare Ltd (REMLIFE) share?
The past returns of Remedium Lifecare Ltd (REMLIFE) share are- Past 1 week: -9.77%
- Past 1 month: -40.15%
- Past 3 months: -55.00%
- Past 6 months: -74.88%
- Past 1 year: -91.91%
- Past 3 years: 104.15%
- Past 5 years: 1228.19%
What are the peers or stocks similar to Remedium Lifecare Ltd (REMLIFE)?
The peers or stocks similar to Remedium Lifecare Ltd (REMLIFE) include:What is the market cap of Remedium Lifecare Ltd (REMLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Remedium Lifecare Ltd (REMLIFE) is ₹101.61 Cr as of 7th March 2025.What is the 52 week high and low of Remedium Lifecare Ltd (REMLIFE) share?
The 52-week high of Remedium Lifecare Ltd (REMLIFE) is ₹33.25 and the 52-week low is ₹2.18.What is the PE and PB ratio of Remedium Lifecare Ltd (REMLIFE) stock?
The P/E (price-to-earnings) ratio of Remedium Lifecare Ltd (REMLIFE) is 3.10. The P/B (price-to-book) ratio is 2.37.Which sector does Remedium Lifecare Ltd (REMLIFE) belong to?
Remedium Lifecare Ltd (REMLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Remedium Lifecare Ltd (REMLIFE) shares?
You can directly buy Remedium Lifecare Ltd (REMLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Remedium Lifecare Ltd
REMLIFERemedium Lifecare Ltd
REMLIFE


Price Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-2.05 | 2.37 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
47.25 | 6.02 | 0.55% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Remedium Lifecare Ltd is a pharmaceutical company engaged in trading and manufacturing active pharmaceutical ingredients (APIs) and intermediates for domestic and international markets, including regulated markets.
Peers
Compare with peersGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 4.26 | 1.43 | 0.37 | 0.25 | 2.89 | 90.03 | 504.79 | 509.84 | 4,062.79 | 1,562.46 | ||||||||||
Raw Materials | 3.65 | 0.71 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 417.30 | 4,127.29 | 1,585.08 | ||||||||||
Power & Fuel Cost | 0.08 | 0.08 | 0.02 | 0.00 | 0.05 | 0.07 | 0.09 | 0.06 | 0.06 | |||||||||||
Employee Cost | 0.05 | 0.04 | 0.13 | 0.04 | 0.18 | 0.19 | 0.21 | 0.55 | 0.40 | |||||||||||
Selling & Administrative Expenses | 0.20 | 0.13 | 0.05 | 0.00 | 0.47 | 1.09 | 3.76 | 6.46 | 4.95 | |||||||||||
Operating & Other expenses | 0.25 | 0.47 | 0.01 | 0.19 | 1.79 | 87.96 | 498.91 | 77.46 | -125.20 | |||||||||||
EBITDA | 0.03 | 0.00 | 0.02 | 0.02 | 0.40 | 0.72 | 1.82 | 8.01 | 55.29 | -22.62 | ||||||||||
Depreciation/Amortization | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.07 | 0.15 | 0.06 | 0.04 | ||||||||||
PBIT | 0.02 | 0.00 | 0.02 | 0.02 | 0.39 | 0.66 | 1.75 | 7.86 | 55.23 | -22.66 | ||||||||||
Interest & Other Items | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.23 | 0.45 | 4.78 | 7.54 | ||||||||||
PBT | 0.01 | 0.00 | 0.02 | 0.02 | 0.38 | 0.64 | 1.52 | 7.41 | 50.45 | -30.20 | ||||||||||
Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.02 | 0.09 | 0.17 | 0.45 | 1.97 | 17.72 | 19.32 | ||||||||||
Net Income | 0.01 | 0.00 | 0.02 | -0.00 | 0.29 | 0.47 | 1.07 | 5.44 | 32.73 | -49.52 | ||||||||||
EPS | 0.00 | 0.00 | 0.00 | -0.00 | 0.01 | 0.01 | 0.03 | 0.13 | 1.48 | -12.28 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Remedium Lifecare Ltd | 3.10 | 2.37 | — |
Sun Pharmaceutical Industries Ltd | 40.32 | 5.75 | 0.84% |
Cipla Ltd | 28.58 | 4.39 | 0.89% |
Torrent Pharmaceuticals Ltd | 62.81 | 15.17 | 0.91% |
Price Comparison
Compare REMLIFE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 4.73%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
REMLIFE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Net profit of Remedium Lifecare declined 98.34% to Rs 0.76 crore in the quarter ended December 2024 as against Rs 45.82 crore during the previous quarter ended December 2023. Sales declined 97.92% to Rs 38.15 crore in the quarter ended December 2024 as against Rs 1834.18 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales38.151834.18 -98 OPM %-14.392.98 - PBDT1.0668.79 -98 PBT1.0568.78 -98 NP0.7645.82 -98 Powered by Capital Market - Live
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 22 January 2025.Powered by Capital Market - Live
Net profit of Remedium Lifecare declined 72.74% to Rs 1.78 crore in the quarter ended September 2024 as against Rs 6.53 crore during the previous quarter ended September 2023. Sales declined 94.65% to Rs 25.08 crore in the quarter ended September 2024 as against Rs 468.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales25.08468.57 -95 OPM %17.781.35 - PBDT2.4710.42 -76 PBT2.4610.41 -76 NP1.786.53 -73 Powered by Capital Market - Live
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 3 September 2024. The meeting will now be held on 4 September 2024.Powered by Capital Market - Live
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live
Net profit of Remedium Lifecare declined 68.76% to Rs 1.64 crore in the quarter ended June 2024 as against Rs 5.25 crore during the previous quarter ended June 2023. Sales declined 76.49% to Rs 77.70 crore in the quarter ended June 2024 as against Rs 330.46 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales77.70330.46 -76 OPM %0.502.20 - PBDT2.287.28 -69 PBT2.277.27 -69 NP1.645.25 -69 Powered by Capital Market - Live
Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 8 August 2024. The meeting will now be held on 14 August 2024.Powered by Capital Market - Live
Remedium Lifecare has entered into a strategic agreement with Angel Partners, UK, effective 29 July 2024, to acquire technology for manufacturing lithium carbonate in India. The company has also signed an annual Supply Agreement with Alfa Chemicals and Solvents, Turkey, effective the same date. Supplies of technical-grade lithium carbonate will commence in the January-March 2025 quarter. The supplies for CY 2025 are valued at USD 20-25 million. Technical-grade lithium carbonate is used in lithium-ion batteries for electric vehicles and portable electronics. Remedium has partnered with various contract manufacturers to produce technical-grade lithium carbonate using the technology from Angel Partners. Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 595.31%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0% to 1.07%